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Illicit drugs are big business. They are 
one of the main profit-generating 
activities of organised crime and are 
estimated to represent around one-fifth 
of global crime proceeds. Every year, 
Europeans spend at least EUR 24 billion 
on illicit drugs. If the sums of money 
spent on these drugs are considerable, 
so too are the costs for our society.
The 2016 EU Drug Markets Report, from 
the EMCDDA and Europol, was launched 
on 5 April in Brussels (1). The report 
provides a state-of-the-art analysis of the 
EU illicit drug market, presenting the 
dynamics and trends along the supply 
chain: from production and trafficking to 
marketing, distribution and consumption. 
The report, and its Strategic Overview, 
describe a market which is constantly 
evolving, adaptable and opportunistic, 
posing a key challenge for policy, law 
enforcement and public health.
Dimitris Avramopoulos, European 
Commissioner for Migration, Home Affairs 
and Citizenship said: ‘Today’s drug 
business criminals are quick to exploit 
and harm global flows of transport, goods 
and people, while posing a threat to public 
health. They use new technology and the 
internet, the growth of global trade and 
commercial infrastructure to perform 
their criminal activities rapidly across 
international borders. In addition, the 
instability in regions neighbouring the EU 
could have potentially profound effects on 
the drug market in Europe. This valuable 
report explores the links to other criminal 
activities and how the illicit income from 
the drug trade can fund migrant 
smuggling and terrorism…’
Europol Director Rob Wainwright added: 
‘ Illicit drug production and trafficking 
remains one of the largest and most 
innovative criminal markets in Europe. 
As it grows more complex and becomes 
entwined with other forms of crime, and 
even terrorism, it represents a key threat 
to the internal security of the EU…’
‘The EU drug market is essentially driven 
by two simple motives: profit and power’, 
continued EMCDDA Director, Alexis 
Goosdeel. ‘Understanding this, and the 
wider impacts of drug markets on 
society, is critical if we are to reduce 
drug-related harm. This knowledge is 
essential for the development of new 
strategies for tackling crime and 
safeguarding the health, security and 
prosperity of our citizens.’
Three themes emerge from the 
analysis: organisational and technical 
complexity, interconnectedness and 
specialisation of groups involved in 
drug markets; accelerated change in 
the market, due to globalisation and 
technology; and the concentration of 
drug market-related activities in a 
number of established and emerging 
geographical ‘hotspots’.
(1) http://europa.eu/rapid/press-release_IP-16-
1241_en.htm
(Left to right) EMCDDA Director Alexis Goosdeel, 
Commissioner Dimitris Avramopoulos and Europol 
Director Rob Wainwright present report at 
European Commission.
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European Drug Report 2016
What are the latest trends in drug supply 
to Europe? What drugs are causing the 
most harm and concern today? What are 
the most recent developments in drug 
prevention, treatment and policy? 
These and other questions will be 
explored by the EMCDDA in its annual 
overview of the European drug situation 
to be launched in Lisbon on 31 May.
The European Drug Report 2016: 
Trends and Developments provides a 
comprehensive analysis of the latest 
tendencies across the 28 EU Member 
States, Turkey and Norway. In print and 
pdf in 24 languages, the report 
examines: drug supply and the market; 
drug use prevalence and trends; and 
drug-related health problems and 
responses to them. 
See next edition of Drugnet Europe for more and 
www.emcdda.europa.eu/edr2016
New report highlights wide-ranging impact 
of drug markets on society
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2016 EU DRUG MARKETS REPORT
CANNABIS
The reality of the cannabis market
Cannabis accounts for an estimated 38 % of the retail market 
for illicit drugs — worth over EUR 9.3 billion annually. 
The benign public image of the cannabis market sits in sharp 
contrast to modern reality, where the industry is linked to 
organised crime. OCGs are heavily involved in this market, 
making full use of technological innovations to produce large 
quantities of more potent and profitable products inside Europe 
itself. Intense competition in the market can lead to extreme 
violence between OCGs. While the European market is 
dominated by herbal cannabis (marijuana) grown within the EU, 
there is evidence of other competing developments. These 
include the trafficking to the EU of high potency cannabis resin 
(hashish) from Morocco, alongside trafficking of other illicit 
goods and human beings. This is a trend potentially 
exacerbated by instability in North Africa and the Middle East.
RAMIFICATIONS
Impacts of drug markets ‘go 
beyond harms caused by use’
The impacts that illicit drug markets have on society are 
wide-ranging and ‘go beyond the harms caused by drug use’, 
states the 2016 EU Drug Markets Report. It describes how drug 
markets impact on our lives in a number of ways through: links 
with other types of criminal activity, including terrorism; their 
effect on legal businesses and the wider economy; the strain 
on, and corruption of, government institutions; and their 
broader negative societal effects (e.g. drug-related crime and 
violence, environmental damage and harms to families and 
communities).
As part of an ongoing project, the report provides an initial 
minimum estimate of the size of the EU illicit drug market. 
Europeans are estimated to spend at least EUR 24 billion per 
year on the main illicit drugs (range: EUR 21 to 31 billion).
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DRIVERS
What factors are driving drug 
market developments?
The EU illicit drug market is becoming increasingly diversified 
and organised crime groups (OCGs) — spurred by the desire for 
profit or power — rapidly exploit new opportunities for 
increasing revenues and evading detection. Analysing the 
factors driving developments can help design appropriate 
responses. The report describes how the rate of change in the 
market is driven and accelerated by globalisation and 
technology. As with other consumer goods, the internet has 
been influential in the drug business, providing both sales 
outlets and opportunities to shorten the supply chain, while 
reducing opportunities for law-enforcement interventions. 
The report proposes that viewing the market from a business 
perspective could help identify new areas for intervention.
OPIOIDS
A dynamic heroin market
Estimated to be worth around EUR 6.8 billion per annum, heroin 
accounts for some 28 % of the illicit drug market. The report 
demonstrates how heroin production techniques and locations, 
trafficking routes and modi operandi are increasingly flexible 
and dynamic. After a period of decline, there are signs of 
increased availability,  suggesting the potential for new 
outbreaks of use.
Opium production remains generally high in Afghanistan and 
there are indications of displacement of heroin production to new 
countries, including some inside Europe. While the Balkan route 
remains a key corridor for heroin entry to the EU, new routes are 
emerging involving Africa, the Southern Caucasus, Syria and Iraq. 
There are also signs of diversification, with prescription medicines 
and new synthetic opioids increasingly misused.
3April–June 2016
2016 EU DRUG MARKETS REPORT
COCAINE
Maritime container transport: 
key mode of cocaine smuggling
The retail market for 
cocaine — Europe’s most 
commonly used illicit 
stimulant — is estimated 
to be worth at least 
EUR 5.7 billion per year. 
Coca cultivation appears 
to be on the rise, after a 
period of decline, but 
there is considerable uncertainty about how much is turned 
into cocaine and where this occurs. Both sea and air transport 
are used to traffic cocaine into Europe, with Colombia, Brazil 
and Venezuela being key departure points. The Caribbean and 
West Africa remain important transit areas, while Central 
America is also emerging in this role. 
Legitimate transport and logistical infrastructures, including 
major European ports, continue to be exploited by drug 
traffickers. Maritime container transport is a key mode of 
cocaine smuggling and a convenient channel for importing 
large consignments of drugs. These practices are challenging to 
detect — Rotterdam for example receives over 20 000 
containers per day.
Colombian and Italian groups continue to dominate wholesale 
cocaine supply to Europe, where they cooperate with other 
(e.g. Dutch, British and Spanish) OCGs. West African, especially 
Nigerian, groups are also active in transporting cocaine from 
Africa to Europe and Balkan OCGs are emerging players.
emcdda.europa.eu/start/2016/drug-markets
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SYNTHETIC DRUGS
Production more sophisticated
The market for amphetamines (amphetamine and 
methamphetamine) is estimated to be worth at least EUR 1.8 
billion annually and for MDMA (ecstasy) some EUR 0.7 billion. 
These synthetic drugs appeal to both recreational and 
marginalised drug users and the market for them interacts with 
those for cocaine and some new psychoactive substances (NPS).
Inside the EU, the Netherlands and Belgium in particular are 
important producers of MDMA and amphetamine, while most 
methamphetamine production occurs in the Czech Republic. 
Production is becoming more sophisticated, for example with 
the use of a decentralised, on-demand model; customised 
equipment; and automated production. Diversification in 
production methods (e.g. use of new drug precursor and 
pre-precursor chemicals) may increase health risks for 
consumers. The dumping of toxic waste from production also 
causes environmental damage and poses health risks to the 
general public.
NEW DRUGS
Over 560 new drugs monitored
There are no signs of a slowdown in the number, type and 
availability of new psychoactive substances (NPS) sold openly 
on the European market. Around 100 new substances were 
reported for the first time in 2015 and the EU Early Warning 
System currently monitors over 560 substances.
Producers anticipate legal and regulatory controls by rapidly 
developing new substances. Globalised supply chains allow 
bulk quantities of NPS to be ordered online and quickly 
transported to Europe where they are packaged and marketed 
on the open, or illicit, drug market. This low-risk, high-profit 
business attracts the involvement of organised crime and there 
are now signs of NPS production inside Europe. Entrepreneurs 
have developed distinct, but overlapping markets, such as ‘legal 
highs’, ‘research chemicals’ and ‘dietary supplements’ sold 
through both ‘bricks and mortar’ and online shops. As NPS 
availability has grown, so too have the harms associated with 
them, such as acute poisonings, which can be fatal.
RESPONSES
Tackling the illicit drug market
The report looks at the main EU policies and strategies 
addressing drug supply reduction and highlights how 
coordinated action at EU level can make a difference in tackling 
the illicit drug trade. It outlines a comprehensive range of 
recommendations and action points in key areas to inform 
future policies and initiatives.
STAKEHOLDERS
‘Meet the authors’ event
The official launch of the 2016 EU Drug Markets Report (see p. 1) 
was followed by a ‘meet the authors’ event at the European 
Commission (EC), co-organised by the EMCDDA, Europol and 
the EC Anti-Drugs Policy Unit of the Directorate-General for 
Migration and Home Affairs. The exhibition-style event brought 
together key stakeholders and experts responsible for the 
analysis to discuss the main issues of the report.
Directors Goosdeel and Wainwright opened the session, 
explaining the purpose of the event: to encourage interaction 
and debate, answer queries and moderate discussions around 
the action points of the report. Operated by specialists from the 
two agencies, four dedicated thematic areas were set up on: 
the impacts of drug markets and market size estimates; natural 
drugs; synthetic drugs and NPS. The online interactive elements 
of the report created the backdrop for the thematic corners and 
stimulated lively discussion and debate.
 Andrew Cunningham, Laurent Laniel and Nicola Singleton  
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BOOKSHELF FEATURE
INCB 2015 
Annual report
The 2015 Annual report from the 
International Narcotics Control Board 
(INCB) was launched in Vienna on 
2 March 2016. Released in the run-up 
to the United Nations General Assembly 
Special Session (UNGASS) on drugs, 
this year’s report contains a chapter 
designed as a specific contribution to 
this session. Entitled ‘The health and 
welfare of mankind: challenges and 
opportunities for the international 
control of drugs’, it recalls that the 
ultimate goal of the three UN drug 
control conventions is to protect public 
and individual health and welfare and 
not to mandate a ‘war on drugs’.
The INCB stresses in the report that 
ensuring the availability of drugs for 
medical purposes and reducing the 
illicit supply of drugs needs to be 
carefully balanced. It also: encourages 
governments to devise realistic 
measures to protect the public from 
the harms posed by NPS; calls on 
governments to ensure that health-
care providers do not overprescribe 
sedatives; and calls for an assessment 
of the state of the international 
precursor control system.
Publisher: United Nations (INCB)
Languages: Arabic, Chinese, English, 
French, Russian and Spanish.
Date: 2 March 2016
ISBN: 978-92-1-148283-6
Downloadable:
www.incb.org/incb/en/news/AR2015/
annual_report_2015.html
The EMCDDA is responsible for the selection of 
materials for the Bookshelf and for the text 
presented. However, responsibility for the content 
of these materials and the opinions expressed 
therein lies with the authors themselves.
EMCDDA presents latest advances in 
monitoring illicit drugs in wastewater 
The latest advances in the science of 
wastewater analysis were presented by 
the EMCDDA on 15 March in a new 
report: Assessing illicit drugs in 
wastewater (1). The report was presented 
in Vienna at an event — ‘Use of 
wastewater analysis to understand drug 
markets’ — being held in the margins of 
the annual meeting of the UN 
Commission on Narcotic Drugs (CND)(2). 
Wastewater analysis is a rapidly 
developing scientific discipline with the 
potential for monitoring near-real-time 
data on geographical and temporal trends in illicit drug use. By sampling a known 
source of wastewater (e.g. a sewage influent to a wastewater treatment plant), 
scientists can estimate the quantity of drugs used in a community by measuring the 
levels of illicit drugs and their metabolites excreted in urine.
The EMCDDA adopts a multi-indicator approach to drug monitoring, on the principle 
that no single measure can provide a full picture of the drug situation. It views 
wastewater analysis as a valuable additional tool in its epidemiological toolkit and one 
which can provide timely information on a wide spectrum of substances.
Launching the report, EMCDDA Director, Alexis Goosdeel, said: ‘Wastewater-based 
epidemiology has demonstrated its potential to become a useful complement to 
established drug monitoring tools. Its ability to deliver almost real-time data on drug 
use patterns is particularly relevant against the backdrop of an ever-shifting drugs 
problem. By detecting changes in drug use patterns, both geographically and over 
time, it can help health and treatment services respond better to emerging trends and 
changing treatment needs’.
The report explores the latest findings from the worldwide application of wastewater-
based epidemiology and the advances that have occurred since 2008. These include 
developments to reduce uncertainties and to standardise procedures, including a 
best-practice protocol developed by the Sewage analysis CORe group Europe 
(SCORE) network (3).
Two case studies (Norway, Italy) show the first attempts to compare cocaine-use 
estimates obtained through wastewater analysis with conventional epidemiological 
data gathered through population surveys. Also described are three new approaches 
for dealing with new psychoactive substances (NPS). These include using pooled 
urine samples from nightclubs and music festivals to provide timely data on which 
NPS are being used and in which locations. Detecting and estimating the use of NPS 
presents a particular challenge for drug epidemiology due to the rapid rise in their 
number and availability.
Finally, the report highlights gaps and requirements for future research, including the 
need for addressing the ethical aspects of wastewater-based epidemiology. 
Better integration of this novel methodology with existing epidemiological indicators 
will allow for a better understanding of the drug situation in Europe.
 Liesbeth Vandam 
(1) Available in English at www.emcdda.europa.eu/publications/insights/assessing-drugs-in-wastewater 
This report updates the first edition published in 2008. 
See also www.emcdda.europa.eu/activities/wastewater-analysis
(2) Organised by the Governments of Italy and Switzerland, UNODC and the EMCDDA.  
For more on the CND session, see www.emcdda.europa.eu/news/2016/cnd
(3) For more, see http://score-cost.eu
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Alexis Goosdeel: ‘Wastewater-based epidemiology 
has demonstrated its potential to become a useful 
complement to established drug monitoring tools’.
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UNGASS 2016
The 2016 UN General Assembly Special Session (UNGASS) on 
drugs convened at the UN headquarters in New York from 
19–21 April (1). This meeting — the third UNGASS dedicated to 
this issue — represented a major political moment and valuable 
opportunity for the international community to review and 
address the world drug problem. 
Via plenary statements, interactive roundtables and some 
50 side events, delegates at UNGASS 2016 reviewed progress 
made in implementing the ‘2009 Political Declaration and Plan 
of Action on international cooperation towards an integrated 
and balanced strategy to counter the world drug problem’ (2).
The meeting adopted an ‘outcome document’ entitled: ‘Our 
joint commitment to effectively addressing and countering the 
world drug problem’ (3). This document places new emphasis 
on a number of themes, including: new trends and emerging 
and persistent challenges and threats (e.g. new psychoactive 
substances and use of the internet); availability of, and access 
to, controlled substances for medical purposes; and the 
treatment of drug use disorders (with a focus on prevention, 
treatment and care of HIV/AIDS). The paper includes 
operational recommendations in areas ranging from demand 
reduction to effective law enforcement and judicial 
cooperation. 
At UNGASS, the EU stood united in reaffirming its commitment 
to the UN international drug control conventions, which provide 
sufficient scope and flexibility to accommodate a wide range of 
approaches to drug policy in accordance with national and 
regional specificities. In its common position, adopted on 
11 November 2015 (4), the EU reiterated the need for countries 
to respect human rights when implementing the international 
conventions. In this context, it called for the abolition of the 
death penalty for drug-related crimes and for proportional 
sentencing and alternative measures to conviction or 
punishment.
The EU delegation, including members of the EMCDDA, was 
headed by Neven Mimica, European Commissioner for 
International Cooperation and Development. On behalf of the EU, 
the Commissioner welcomed the re-balancing of global drug 
policies towards a multi-disciplinary, public health and human 
rights approach. He also stressed how effective drug policies must 
be based on evidence and reliable monitoring systems. Following 
the adoption of the outcome document, the EU presented an oral 
statement — on behalf of the Member States and 28 third 
countries — regretting the non-inclusion in the statement of the 
abolition of the death penalty for drug-related offences.
 Danilo Ballotta 
(1) www.unodc.org/ungass2016 | www.emcdda.europa.eu/news/2016/
ungass-2016
(2) www.unodc.org/documents/ungass2016/V0984963-English.pdf  
This document renewed the 10-year commitment to reducing illicit supply and 
demand for drugs by 2008, made at the last UNGASS on drugs in 1998.
(3) www.emcdda.europa.eu/system/files/attachments/2354/E_CN7_2016_
L12_Rev.1.pdf
(4) www.unodc.org/documents/ungass2016//Contributions/IO/EU_
COMMON_POSITION_ON_UNGASS.pdf
INTERNATIONAL
DRUGS-LEX
Upcoming UK law to control distribution of NPS
The Psychoactive Substances Act 2016, approved by the UK 
Parliament at the beginning of this year, is due to come into 
force this Spring (1). The law is designed to prevent 
manufacturers and suppliers from continually replacing 
recently controlled psychoactive substances with non-
controlled alternatives. 
The act defines a psychoactive substance as ‘any substance 
which is capable of producing a psychoactive effect in a 
person who consumes it’. This means a substance which, by 
stimulating or depressing the person’s central nervous system, 
affects the individual’s mental functioning or emotional state. 
The act specifically excludes: controlled drugs; medicinal 
products; alcohol; nicotine and tobacco products; caffeine 
and food. Other substances may also be excluded in future.
The act prohibits producing, supplying (or possessing with 
intent to supply), importing or exporting a psychoactive 
substance when there is the intention or knowledge that the 
substance will be consumed for its psychoactive effects. 
Supply offences are aggravated by the following factors: 
proximity to a school; using a minor as a courier; or being 
carried out in a custodial institution. The maximum penalties 
specified in the act are seven years’ imprisonment on 
indictment or one year on summary conviction. Possession of 
a psychoactive substance (not for supply) in a custodial 
institution is punishable by up to two years’ imprisonment on 
indictment or one year on summary conviction; otherwise, 
there is no offence for possession for personal use (except in 
custodial institutions). 
The Psychoactive Substances Act 2016 operates alongside 
the amended Misuse of Drugs Act 1971 and its system of 
Temporary Drug Control Orders (2).
 Brendan Hughes and Angela Scrutton 
(1) The Psychoactive Substances Act 2016: 
www.legislation.gov.uk/ukpga/2016/2/contents/enacted
(2) www.emcdda.europa.eu/publications/drugnet/online/2011/76/article13
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UNGASS 2016: a major political 
moment and valuable 
opportunity for the international 
community to review and 
address the world drug problem.
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Strengthening early warning on new synthetic 
opioids
As revealed in the 2016 EU Drug Markets 
Report, around 100 new psychoactive 
substances (NPS) were reported through 
the EU Early Warning System for the first 
time in 2015. Once again, the list of 
substances reported was dominated by 
two groups: synthetic cannabinoids and 
synthetic cathinones. Together these 
represent 61 % of the NPS seized in 
Europe in 2014.
Concerns are growing, however, over the 
number of new synthetic opioids being 
detected on the European market, 
despite the comparatively small amounts 
seized. A total of 19 new synthetic 
opioids — including 11 fentanyls — have 
been detected since 2009, most of which 
have emerged in the last three years. 
New synthetic opioids are of particular 
concern as they can pose a very high risk 
of serious poisoning or even death. 
In the course of 2014, following deaths 
reported in a number of EU countries, 
the EMCDDA Scientific Committee risk 
assessed a synthetic opioid known as 
AH-7921 — the first opioid to be 
assessed (1). This was closely followed by 
another synthetic opioid MT-45 (2). 
In 2015, deaths in Europe linked to 
acetylfentanyl prompted the EMCDDA 
and Europol to produce a Joint Report on 
this substance (3). Responding to these 
concerns, the EMCDDA organised in 
Lisbon on 31 March and 1 April 2016 a 
technical meeting bringing together a 
multi-disciplinary group of experts. 
The aim of the meeting was to discuss 
the challenges posed by these 
substances and to identify practical 
ways in which early-warning systems 
could be strengthened in order to reduce 
harms to society. A summary of findings 
will be published in the coming months.
 Rita Jorge and Michael Evans-Brown 
(1) www.emcdda.europa.eu/publications/
risk-assessment/AH-7921
(2) www.emcdda.europa.eu/publications/
risk-assessment/mt-45
(3) To be published in the coming weeks.
NEW PSYCHOACTIVE SUBSTANCESSPOTLIGHT
Drugs in prison
Nelson Mandela Rules
The ‘United Nations Standard Minimum 
Rules for the Treatment of Prisoners’ 
— the ‘Nelson Mandela Rules’ — were 
published in December 2015. The 
standards set out guiding principles for 
the treatment of people living in prison, 
following the principles of the Universal 
Declaration of Human Rights.
Specific rules target the issue of health 
treatment, formalising the principles 
of: equivalence and continuity of care 
between prison and the community; 
independence of healthcare 
professionals; and requirement to treat 
people suffering from drug-related 
problems (rules 24, 27, 30). The rules 
represent an important step forward at 
global level in the field of human rights 
and access to healthcare for people 
living in prison.
For more, see www.un.org/en/ga/search/
view_doc.asp?symbol=A/RES/70/175
European penal statistics
The latest European annual penal 
statistics (2014) were published by the 
Council of Europe and the University of 
Lausanne in December 2015. 
The report is based on data from the 
annual SPACE survey, involving 52 
prison administrations in 47 Council of 
Europe Member States, gathered via a 
common questionnaire filled in by 
national correspondents in each prison 
administration. The document provides 
data on population, conditions of 
detention and custodial movement 
concerning: populations held in 
custody; people serving non-custodial 
sanctions; and penal population 
supervised in the community.
For more, see http://wp.unil.ch/space/
files/2016/03/Council-of-Europe_
SPACE-I-2014__Final_160308.pdf
 Linda Montanari 
Drug supply data-collection training for ENP 
countries 
‘Data collection and reporting on drug 
seizures’ was the title of a two-day 
Reitox Academy organised by the 
EMCDDA from 17–18 March in 
Budapest. The training seminar — 
hosted by the European Police College 
(CEPOL) and targeting beneficiary 
countries of the European 
Neighbourhood Policy (ENP) — 
welcomed delegates from Georgia, the 
Republic of Moldova and Ukraine.
The purpose of the event was to provide 
specific training on the use of 
established EMCDDA data-collection 
tools and methodologies to allow 
participants to systematically collect, 
analyse and report national drug seizure 
data. In the days following the training 
session, the participants embarked on a 
retrospective data- and information-
gathering exercise in the three countries 
concerned, spanning a five-year period 
(2011–15). 
The training and data-collection exercise 
were organised under a project, ‘Towards 
a gradual improvement of ENP partner 
countries’ capacity to monitor and to 
meet drug-related challenges’, currently 
being implemented by the EMCDDA and 
financed through the European 
Neighbourhood and Partnership 
Instrument (ENPI) of the European 
Commission (1).
 Andrew Cunningham, Teodora Groshkova  
 and Frédéric Denecker 
(1) http://ec.europa.eu/europeaid/funding/
european-neighbourhood-and-partnership-
instrument-enpi_en
REITOX
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 Concerns are growing over  
 the number of new synthetic  
 opioids being detected on  
 the European market 
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PRODUCTS AND SERVICES EVENTS
Healthy Nightlife Toolbox
The Healthy Nightlife Toolbox (HNT) is 
a European website focusing on the 
reduction of harm from alcohol and 
drug use among young people in 
nightlife settings. It will be launched at 
a meeting of the EU National Drug 
Coordinators on 2 May in Amsterdam. 
The aim of the toolbox is to support the 
identification and implementation of 
effective interventions in this setting.  
The first version of the HNT, supported 
by the EU, was created between 2008 
and 2010, following cooperation 
between partners from Belgium, Spain, 
Hungary, the Netherlands and the UK. 
Now, in 2016, under its EU Presidency, 
the Dutch government is financially 
supporting the update of this valuable 
resource. From May 2016, the HNT will 
be informing local, regional and 
national policymakers and prevention 
workers in the EU on evidence-based 
and best-practice interventions in 
nightlife settings. The EMCDDA will 
host the website in 2017.
For more, see www.hntinfo.eu and  
english.eu2016.nl/events/2016/05/02/
meeting-of-national-drugs-coordinators
European drugs summer 
school 2016
The University Institute of Lisbon 
(ISCTE-IUL) and the EMCDDA will be 
holding the fifth European drugs 
summer school (EDSS) on ‘Illicit drugs 
in Europe: demand, supply and public 
policies’ from 27 June to 8 July in 
Lisbon. This year, the focus of the 
course will be on the evidence base for 
policymaking on drug-related issues. 
Keynote speakers will consider the 
outcomes of the 2016 United Nations 
General Assembly Special Session on 
Drugs (UNGASS). The second phase of 
registration will run until 30 May.
For more see www.drugsummerschool.cies.
iscte-iul.pt/np4/home
2016 EU Drug Markets Report
The 2016 EU Drug Markets Report, 
from the EMCDDA and Europol, was 
launched in Brussels on 5 April 
(see pp. 1–3). The extensive 188-page 
In-depth Analysis provides a unique 
insight into the operations of illicit 
drug markets in the EU and assesses 
their ramifications for society as well 
as key drivers of change. The report 
reviews the markets for cannabis, 
heroin, cocaine, amphetamine, 
methamphetamine, MDMA and new 
psychoactive substances and provides concrete action points to inform policy 
development at EU and national level. The report is accompanied by a Strategic 
Overview, providing a summary of key findings, and additional supporting material.
In-depth Analysis (EN) www.emcdda.europa.eu/publications/eu-drug-markets/2016/in-depth-analysis
Strategic Overview (ES, DE, EN, FR, PT) 
www.emcdda.europa.eu/publications/eu-drug-markets/2016/strategic-overview
Assessing illicit drugs in wastewater 
The latest EMCDDA Insights launched on 15 March — 
Assessing illicit drugs in wastewater: advances in wastewater-
based drug epidemiology — reviews a novel approach to 
estimating drug use in populations, based on the detection 
and quantification of drugs and their metabolic products in 
community wastewater. Strengths of the wastewater-based 
approach include avoiding the problems associated with 
questionnaire-based research, better identification of the 
drugs being used and ability to provide near-real-time results.
 Available in English. See news release at www.emcdda.europa.eu/
news/2016/emcdda-presents-latest-advances-wastewater-analysis
The internet and drug markets 
How do online drug markets function? What technologies do 
they use? How do they relate to the traditional drug market? 
How can they be monitored and controlled? The complexities 
of these questions are unravelled in an EMCDDA Insights 
published on 11 February: The internet and drug markets. 
This new EMCDDA investigation into the world of online drug 
markets brings together state-of-the-art evidence from over 
20 experts and contributes to the knowledge base on this 
part of the supply chain. 
Available in English. See news release at www.emcdda.europa.eu/
news/2016/2/internet-drug-markets
Drugnet Europe subscriptions 
After 20 years of delivering you Drugnet Europe in print, the EMCDDA is phasing out 
the print edition. To ensure that you keep up to date with EMCDDA activities, we would 
like to offer you the opportunity to switch to an electronic subscription. To update your 
data, or cancel your current subscription, please visit the link below to enter the 
subscription number appearing on the postal address label.
Update at http://surveys.publications.europa.eu/formserver/emcdda/mailing_list.html
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EMCDDA meetings
11–12 May: 44th EMCDDA Scientific Committee 
meeting, Lisbon.
19–20 May: 16th annual meeting of the Reitox Early 
Warning System network, Lisbon.
26 May: Budget Committee meeting, Lisbon.
27 May: Executive Committee meeting, Lisbon.
31 May: Launch of the European Drug Report 
2016, Lisbon.
21–22 June: 17th annual meeting of the legal 
correspondents of the ELDD, Lisbon.
23 June: Budget Committee meeting, Lisbon.
23 June: Executive Committee meeting, Lisbon.
23–24 June: 53rd EMCDDA Management Board 
meeting, Lisbon.
External meetings
19–21 April: UNGASS 2016, New York.
4–7 May: Substance Abuse Librarians and 
Information Specialists (SALIS), 
38th International Conference, Denver.
30 May: 19th MedNET meeting, Pompidou 
Group, Strasbourg.
11–13 June: NIDA International Forum, Palm 
Springs.
26 June: International Day against Drug Abuse 
and Illicit Trafficking.
EU meetings
2 May: National Drug Coordinators’ meeting, 
Dutch Presidency.
9 May: Europe Day.
11–12 May: Horizontal working party on drugs and 
EU-CELAC meeting, Brussels.
25 May: Meeting of the Heads of EU agencies, 
Brussels.
7–8 June: Expert meeting on the internet and 
drugs, European Commission 
(DG-HOME), Brussels.
9 June: Horizontal working party on drugs, 
Brussels.
EMCDDA scientific paper award
The EMCDDA Scientific Committee is currently assessing 
eligible nominations for the sixth round of the EMCDDA 
scientific paper award. The nomination phase ran between 
January and February, leading to 53 articles being nominated 
by: editors of peer-reviewed journals; European research 
societies; the Reitox national focal points; members of the 
EMCDDA Scientific Committee and EMCDDA staff members. 
The nominated articles, published in 2015 in a peer-reviewed 
journal, are judged to enhance knowledge and understanding in 
the area of illicit drugs and new psychoactive substances. 
They also have a clear European focus or a primary author being 
a European citizen or based in Europe. The Scientific 
Committee will agree on a shortlist of articles at its next 
meeting from 11–12 May. These articles will be rated by a jury 
composed of top-level experts in each of the five research 
categories (1). Up to five winners may be acknowledged at a 
ceremony at the EMCDDA in the autumn.
 Maria Moreira 
(1) Basic biological, neurobiological and behavioural research; population- 
based and clinical epidemiology; demand reduction; supply, supply reduction 
and crime; and drug policy.  
For more, see www.emcdda.europa.eu/activities/scientific-paper-award
Upcoming ESPAD report
The latest European data on substance use among 15–16-year-
old students (2015) will be published by the European school 
survey project on alcohol and other drugs (ESPAD) in 
September 2016 (1). ESPAD has been collecting data through 
school surveys every four years since 1995, the latest wave 
coinciding with its 20th anniversary. 
A common questionnaire and methodology are used to achieve 
a sound level of comparability across countries and over time. 
The questionnaire includes a section on illegal drugs, but also a 
substantial part relating to alcohol. The number of countries 
participating in the survey has increased over the years: 
35 countries participated in the 2015 survey 
(100 000 respondents). 
The 2015 ESPAD report will be presented at the EMCDDA in 
Lisbon on 20 September following a meeting of the EMCDDA 
general population surveys (GPS) expert group. Over the last 
two years, the EMCDDA has scaled up its support for ESPAD 
and is now a member of its coordination group (2).
 Julián Vicente 
(1) See Drugnet Europe 95 for more.
(2) www.emcdda.europa.eu/about/partners/espad
